Suggested Readings

Diagnosis and management of multiple myeloma: a review.

Cowan AJ, et al. JAMA. 2022;327(5):464-477.  

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Rajkumar SV. Am J Hematol. 2022;97(8):1086-1107. 

Targeting BCMA in multiple myeloma.

Tan CR, Shah UA. Curr Hematol Malig Rep. 2021;16(5):367-383.  

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

Lonial S, et al. Lancet Oncol. 2020;21(2):207-221. 

Idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Munshi NC, et al. N Engl J Med. 2021;384(8):705-716. 

Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up.

Martin T, et al. J Clin Oncol. 2022;JCO2200842. 

Teclistamab in relapsed or refractory multiple myeloma.

Moreau P, et al. N Engl J Med. 2022;387(6):495-505. 

The emerging therapeutic landscape of relapsed/refractory multiple myeloma.

Tanenbaum B, et al. Ann Hematol. 2023;102(1):1-11.  

Revised International Staging System for Multiple Myeloma: a report from International Myeloma Working Group.

Palumbo A, et al. J Clin Oncol. 2015;33(26):2863-2869.  

Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.

Morris EC, et al. Nat Rev Immunol. 2022;22(2):85-96. 

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: results from Cohort A of the Magnetismm-3 study.

Bahlis NJ, et al. Accessed December 12, 2022.

 

Linked Resources

Guidelines

NCCN Guidelines® insights: multiple myeloma, version 3.2022.

Callander NS, et al. J Natl Compr Canc Netw. 2022;20(1):8-19.

Clinician Resources

International Myeloma Working Group

Multiple Myeloma Research Foundation

Related activities
 
1.00 CME/AANP

Lifting the Bar in Relapsed or Refractory Multiple Myeloma

Capitalizing on BCMA-Directed Therapies

Faculty: Joseph Mikhael, MD, MEd, FRCPC, FACP; Krina K. Patel, MD, MSc
Release: 01/31/2023
Expiration: 01/31/2024
Begin Activity